Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DnaJ heat shock protein family (Hsp40) member C28 (DNAJC28) is a protein-coding gene located on chromosome 21, encoding a 388-amino-acid protein that functions as a member of the DnaJ (Hsp40) co-chaperone family[2][3][5][6]. The protein contains a conserved N-terminal J-domain, essential for interaction with Hsp70 chaperones involved in ATPase regulation and protein folding[2][3][10]. DNAJC28 is thought to facilitate proper folding of newly synthesized proteins, act as a molecular chaperone to prevent aggregation, contribute to protein quality control, and participate in vesicle transport processes within the Golgi[1][2][7]. There is no current evidence that DNAJC28 itself is a therapeutic target; it is classified as a molecular chaperone, not a receptor, enzyme, transporter, or traditional drug target[3][6][11]. Disease associations are not well defined, though variants have been annotated with rare neuronopathy phenotypes[3]. There are no known drugs targeting DNAJC28, and no established biomarker or safety concerns linked specifically to this gene[3][10][12].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DnaJ heat shock protein family (Hsp40) member C28 (DNAJC28).